Landing Med
Landing Med, the trading name of Wuhan Landing Intelligence Medical Co., Ltd., sells an end to end system for AI cervical cancer screening. A laboratory can buy every step from the company: liquid based cytology collection kits and stains, a slide preparation machine, the LD Cyto2200 high throughput or LD Patho portable slide scanners, and LD CytoBrain, a deep learning model trained on more than 10 million cervical samples and a billion labeled cells that flags abnormal cells for a cytopathologist to review before the report goes out.
CytoBrain runs two ways. The on premise version works fully offline, so slide images never leave the lab. The cloud version lets several reviewers log in from anywhere, and Landing Med can also supply a pathologist's reading. The company says it has screened more than 10 million women, including a Hubei provincial program from 2022 that aimed to reach 12 million women aged 35 to 64 through more than 1,200 hospitals and clinics, and it cites a 2020 paper in Cancer Medicine reporting 90.1% sensitivity and 94.8% specificity for CIN2 or worse.
The site shows CE and NMPA marks and ISO 9001, 14001, 15189 and 45001 logos without naming the product or class each covers. Buyers are laboratories, hospitals and government screening programs in China and abroad, with customers named in Pakistan and Singapore. No prices are published. Founded in 2000 and based in Wuhan, Hubei, China.
Capability Axes
An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read
CytoBrain is what makes the system an AI screening product: a deep learning model that reads scanned cervical cytology slides and flags abnormal cells and areas of interest for a cytopathologist. The company sells it inside a complete laboratory workflow, though, and much of that workflow is hardware and consumables that stand on their own: collection kits, preservation solution and stains, a slide preparation machine and digital slide scanners that research labs buy for other pathology work.
The model is the engine of the screening product, and the scanner and consumable lines would still sell without it.
The published workflow places a pathologist between the AI and the report: sample collection, slide preparation, scanning, AI analysis, pathologist review, then the digital report. The model flags areas of interest to support the cytopathologist.
The same pages say the model processes slides autonomously and reduces reliance on human pathologists, and nothing says which slides a pathologist actually sees. Whether slides the model calls negative are reported without human review, the confidence level that sends a slide to a person, and how a missed abnormal cell is caught later are not described.
The model is named and its training data characterized: LD CytoBrain, a deep learning model trained on more than 10 million cervical samples and over a billion labeled cells, reading whole slide images from the company's own LD Patho 320A and LD Cyto2200 scanners. The full pipeline around it is described, from liquid based collection through automated slide preparation and staining to scanning.
No version, update schedule or notice of model change is published, and the pages do not say whether the on premise and cloud versions run the same model.
The chain is short. CytoBrain is the company's own model, run on its own scanners, and the on premise version is fully offline, so in that setup no outside party receives patient data at all.
The cloud version adds parties that are not named: no hosting provider, region or subprocessor is listed, and the pathologist reading service is the company's own staff or partners, which the pages do not specify.
The company cites a 2020 paper in Cancer Medicine reporting 90.1% sensitivity and 94.8% specificity for CIN2 or worse, and lists further publications in Gynecologic Oncology (2020), The Lancet Regional Health Western Pacific (2023) and the WHO Bulletin (2023). A Tsinghua University public health professor is quoted endorsing its end to end screening model.
Deployment is large and named. A Hubei provincial program from 2022 set out to screen 12 million women aged 35 to 64 through more than 1,200 hospitals and clinics, the company says its lab once screened 1 million cases in 50 days, and it counts more than 10 million women screened in all, with programs in Tibet and with mobile screening buses. The case studies give scale rather than outcome figures, and the study designs and populations behind the published accuracy figures are not summarized on the company's pages.
Privacy is offered as an architecture choice rather than a policy. The on premise CytoBrain runs entirely offline, with no cloud dependency, so slide images and results stay on site, which the company presents as safeguarding patient privacy.
For the cloud service nothing is stated: how long uploaded slide images and reports are kept, whether they are de identified, and whether they feed further training of a model already built on more than 10 million samples. Nothing is said about guardrails on the model's output or how an error found after a report is handled.
No privacy position for patient data is stated under HIPAA, China's personal information law or any other regime. The only privacy document is a short website policy covering names, addresses and payment details collected through the site.
The on premise version is described as working fully offline so that all data stays in the lab, which keeps slide images away from the company. The cloud version, which uploads slide images for remote review and can return a Landing Med pathologist's opinion, has no published terms for how that patient data is handled.
No security certification or outside security test is published. The ISO logos on the site cover quality management (9001), environmental management (14001), occupational health and safety (45001) and medical laboratory quality (15189), none of which audits information security, and there is no security page or description of controls for the cloud service.
The cloud product holds cervical cytology images and reports, so the gap falls hardest on laboratories that choose it over the offline version.
The home page shows CE and NMPA marks in its certifications strip, beside ISO 9001, 14001, 15189 and 45001 logos, without naming which product each mark covers, its class, certificate number or date. No FDA clearance is claimed, and the product is not marketed to US buyers.
The product makes a clinical claim, detecting abnormal cervical cells and supporting the diagnosis, so the regulatory position matters to a buyer. Whether CytoBrain itself carries an NMPA registration or a CE mark under the in vitro diagnostic rules, or whether the marks cover the scanners and consumables, is not stated in text.
Nothing is published on how the model is governed or tested across groups. The quality system logos (ISO 9001, and ISO 15189 for medical laboratories) describe manufacturing and the company's own lab rather than model behavior.
Cytology models are sensitive to how slides are prepared, stained and scanned, and to the population screened. A model trained largely on samples from Chinese screening programs and the company's own preparation method will meet other stains, slide preparations and populations abroad, and no results are given by preparation method, scanner, age group or HPV status.
A pathologist review step sits in the published workflow before the digital report, and the flagged areas of interest let the reviewer check what the model saw. That is the mechanism for catching an error.
Nothing stands behind the output itself. No accuracy commitment, warranty, remediation process or route for a patient whose result was wrong is published, and the company does not say what it does when a missed abnormality is found after a report.
The Hubei program is described as integrating the AI system into the provincial health data network, linking more than 1,200 hospitals and clinics so results and follow up alerts flow through it, and cloud reports can be issued digitally.
No laboratory information system, EHR, interface standard or file format is named, so how CytoBrain results reach a hospital's own systems outside that program is not described.
Two options are offered. The on premise CytoBrain runs entirely offline on site, with slide data never leaving the laboratory. The cloud version uploads scanned slides for AI analysis and remote review by multiple users, from anywhere.
Where the cloud service runs, which country holds uploaded slides, and how customers are kept apart are not stated, which matters for laboratories outside China sending patient images to the cloud version.
No price is published, but the shape of the sale is clear. A laboratory can buy the full chain (collection kits and stains, a slide preparation machine, a high throughput or portable scanner, and the CytoBrain software on premise or in the cloud) or pieces of it, and the cloud service can include a pathologist's reading from Landing Med. Scanners are pitched as cost effective for labs from a few slides a day to several hundred.
Whether CytoBrain is licensed per slide, per case, per scanner or by subscription, and what the reading service costs, are not stated, and every product page ends in a contact form.
The use is narrow and named: cervical cancer screening by liquid based cytology, for laboratories, hospitals and government screening programs, with women aged 35 to 64 as the Hubei program's target group. The company also mentions DNA ploidy work for oral cancer and sells its scanners to pathology research labs.
Named deployments back part of it: the Hubei provincial program, screening in Tibet and by mobile bus in rural China, a cytopathologist at Jinnah Sindh Medical University in Karachi quoted on the scanners, and a scanner installation in Singapore. Performance outside the Chinese program, with other stains, slide preparation methods and populations, is not reported on the company's pages.
Alternatives to Landing Med
Other products that do the same kind of work as Landing Med, and what each one does.
Techcyte sells Fusion, a digital pathology platform that human, veterinary and environmental laboratories use for both anatomic and clinical pathology.
Genius Cervical AI is Hologic's AI for cervical cancer screening. Cytology laboratories buy it as part of the Genius Digital Diagnostics System, which scans Pap test slides so staff can review them on screen instead of under a microscope.
AIRA Matrix, from AIRA Matrix Private Limited of Thane, India, sells deep learning image analysis for pathology to drug developers and laboratories.
Pramana makes whole slide imaging scanners that use real time AI during acquisition: quality control that detects artifacts such as bubbles, folds, debris and faint tissue and rescans automatically, tissue detection and region selection, and edge algorithms for feature detection while the…
Tribun Health sells CaloPix, software that pathology laboratories use to manage cases and review scanned slides on screen.
Visiopharm sells pathology image analysis software for diagnostics and research, with its diagnostic products packaged as APPs: deep learning algorithms that score HER2, Ki67, ER and PR and detect metastases in breast cancer, score PD-L1 in non-small cell lung cancer, and assess prostate…
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Not published.
|
Landing Med sells the cervical screening chain as a system or in parts: collection kits and stains, a slide preparation machine, scanners, and CytoBrain AI software on premise or as a cloud service that can include a pathologist's reading. Sales run through a contact form. | Not published. No HIPAA or business associate position is stated; the on premise version keeps slide data in the laboratory. | Not published. | Vendor Published |
Landing Med sells hardware, consumables and AI software for cervical cytology to laboratories, hospitals and screening programs, with scanners pitched for labs handling anywhere from a few slides to several hundred a day. No price is published for any item, and whether CytoBrain is charged per slide, per case, per scanner or by subscription is not stated.